Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes
- 9 November 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 98 (2), 339-350
- https://doi.org/10.1007/s00277-018-3539-7
Abstract
The impact of iron chelation therapy (ICT) on overall survival (OS) and progression to acute myeloid leukemia (AML) in patients with iron overload and International Prognostic Scoring System low- or intermediate-risk myelodysplastic syndromes (MDS) is not well understood. We conducted a systematic review and meta-analysis of published studies of ICT in patients with MDS to better elucidate these relationships. We searched PubMed, EMBASE, Cochrane databases, and the World Health Organization Clinical Trial Registry for studies reporting the impact of ICT on OS in patients with low- or intermediate-risk MDS. Studies were examined for demographics, effect measures, and potential bias risk. Fixed and random-effects models were used to calculate adjusted OS and adjusted hazards ratio (aHR) estimates, respectively, among the different studies. Nine observational studies (four prospective and five retrospective) were identified. For patients with MDS, ICT was associated with an overall lower risk of mortality compared with no ICT (aHR 0.42; 95% confidence interval (CI) 0.28–0.62; P < 0.01); however, there was significant heterogeneity across the studies. In studies reporting progression to AML, ICT was not associated with decreased risk of progression (odds ratio 0.68; 95% CI 0.31–1.43; P < 0.030). This systematic review and meta-analysis of nine nonrandomized trials demonstrated significant reduction in risk of mortality in patients with iron overload and low- or intermediate-risk MDS treated with ICT; however, a causal relationship cannot be established. Randomized, controlled trials are needed to more definitively evaluate the relationship between ICT and survival in patients with iron overload and low- or intermediate-risk MDS.Keywords
This publication has 55 references indexed in Scilit:
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- Controversies surrounding iron chelation therapy for MDSBlood Reviews, 2011
- Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFMLeukemia Research, 2010
- Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practicesTransfusion, 2009
- Consensus statement on iron overload in myelodysplastic syndromesAmerican Journal of Hematology, 2008
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsBlood, 2008
- Myelodysplastic syndromesBlood, 2008
- Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromesLeukemia Research, 2007
- Elevated Serum Transferrin Saturation and MortalityAnnals of Family Medicine, 2004
- Confronting publication bias: A cohort design for meta‐analysisStatistics in Medicine, 1987